JP2015508757A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508757A5 JP2015508757A5 JP2014556052A JP2014556052A JP2015508757A5 JP 2015508757 A5 JP2015508757 A5 JP 2015508757A5 JP 2014556052 A JP2014556052 A JP 2014556052A JP 2014556052 A JP2014556052 A JP 2014556052A JP 2015508757 A5 JP2015508757 A5 JP 2015508757A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- variable region
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261595902P | 2012-02-07 | 2012-02-07 | |
| US61/595,902 | 2012-02-07 | ||
| US201261625841P | 2012-04-18 | 2012-04-18 | |
| US61/625,841 | 2012-04-18 | ||
| PCT/EP2013/052439 WO2013117647A1 (en) | 2012-02-07 | 2013-02-07 | Mica binding agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508757A JP2015508757A (ja) | 2015-03-23 |
| JP2015508757A5 true JP2015508757A5 (enExample) | 2016-03-31 |
| JP6405242B2 JP6405242B2 (ja) | 2018-10-17 |
Family
ID=47714068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014556052A Active JP6405242B2 (ja) | 2012-02-07 | 2013-02-07 | Ｍｉｃａ結合剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10577416B2 (enExample) |
| EP (1) | EP2812027A1 (enExample) |
| JP (1) | JP6405242B2 (enExample) |
| CN (1) | CN104244977A (enExample) |
| AU (1) | AU2013218017B2 (enExample) |
| BR (1) | BR112014019611A2 (enExample) |
| CA (1) | CA2862101A1 (enExample) |
| IL (1) | IL233793B (enExample) |
| RU (1) | RU2656183C2 (enExample) |
| SG (1) | SG11201404177PA (enExample) |
| WO (1) | WO2013117647A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3210625B1 (en) * | 2011-09-30 | 2019-08-28 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica) |
| BR112014019611A2 (pt) | 2012-02-07 | 2017-06-27 | Innate Pharma | agentes de ligação mica |
| CA2906356A1 (en) | 2013-03-15 | 2014-09-18 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
| WO2014144791A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| WO2015085210A1 (en) | 2013-12-06 | 2015-06-11 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| WO2015139020A2 (en) | 2014-03-14 | 2015-09-17 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
| US11453713B2 (en) * | 2014-12-05 | 2022-09-27 | Xyphos Biosciences Inc. | Insertable variable fragments of antibodies and modified A1-A2 domains of NKG2D ligands |
| WO2016154585A1 (en) | 2015-03-26 | 2016-09-29 | Charles Sentman | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| US10736963B2 (en) | 2015-07-24 | 2020-08-11 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| TN2018000187A1 (en) * | 2015-12-04 | 2019-10-04 | Dana Farber Cancer Inst Inc | Vaccination with mica/b alpha 3 domain for the treatment of cancer |
| WO2017147247A1 (en) * | 2016-02-23 | 2017-08-31 | Pires Eusebio S | Anti-sas1b antibodies and methods of use |
| WO2017157895A1 (en) | 2016-03-15 | 2017-09-21 | Innate Pharma | Anti-mica antibodies |
| CN107779433A (zh) * | 2016-08-30 | 2018-03-09 | 天津市康婷生物工程有限公司 | 便捷的刺激nk细胞增殖和分化的饲养层制备方法 |
| JP2020502042A (ja) | 2016-10-19 | 2020-01-23 | ノヴェロジックス・バイオテクノロジー，インコーポレーテッド | Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 |
| CN107964041B (zh) * | 2016-10-20 | 2023-08-01 | 中国科学院广州生物医药与健康研究院 | 高稳定性和高亲和力的dmic及其制法 |
| US11555076B2 (en) | 2016-10-29 | 2023-01-17 | Genentech, Inc. | Anti-MIC antibodies and methods of use |
| CA3047833A1 (en) * | 2016-12-22 | 2018-06-28 | Icahn School Of Medicine At Mount Sinai | Anti-lilrb3 antibodies and methods of use thereof |
| WO2018141959A1 (en) | 2017-02-06 | 2018-08-09 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
| EP3661552A4 (en) * | 2017-05-22 | 2021-08-25 | Dana-Farber Cancer Institute, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING THE ELIMINATION OF MICA / B |
| JP2020527144A (ja) * | 2017-07-10 | 2020-09-03 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 癌を処置するためのヒトｓｉｇｌｅｃ−９に対する抗体およびヒトｎｋｇ２ａに対する抗体を使用する組み合わせ療法 |
| JP7274469B2 (ja) * | 2017-10-06 | 2023-05-16 | イナート・ファルマ・ソシエテ・アノニム | Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復 |
| JP7351845B2 (ja) * | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| IL280487B2 (en) * | 2018-07-31 | 2025-07-01 | Cullinan Mica Corp | Anti-mica/b antibodies that block mica/b shedding and methods of use |
| WO2020035345A1 (en) | 2018-08-14 | 2020-02-20 | Innate Pharma | Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody |
| CA3148318A1 (en) * | 2019-08-23 | 2021-03-04 | Jennifer D. Wu | Materials and methods for activating antigen-specific t cell responses |
| KR20220137882A (ko) * | 2019-12-05 | 2022-10-12 | 바이셀릭스, 인크. | 보편적 세포 요법을 위한 면역 회피 기작의 조절제 |
| CN111471099B (zh) * | 2020-03-31 | 2022-04-12 | 长沙学院 | MICA胞外区突变体及其筛选的方法、scFv-MICA融合抗体及其制备方法和应用 |
| CN111718416B (zh) * | 2020-06-25 | 2022-04-01 | 菲鹏生物股份有限公司 | 抗硫氧还蛋白的抗体、其应用和诊断试剂盒 |
| TW202216776A (zh) | 2020-07-07 | 2022-05-01 | 美商康愈有限責任公司 | Mic抗體及結合劑以及其使用方法 |
| EP4192876A1 (en) | 2020-08-10 | 2023-06-14 | Innate Pharma | Cell surface mica and micb detection using antibodies |
| CN112694532B (zh) * | 2021-01-12 | 2023-04-18 | 倍而达药业（苏州）有限公司 | 抗Siglec-15的抗体或其抗原结合片段及应用 |
| CN113502265B (zh) * | 2021-05-25 | 2024-05-28 | 昭泰英基生物医药（香港）有限公司 | 将t细胞重编程为类nk细胞的诱导剂及其应用 |
| CN115611982B (zh) * | 2021-07-14 | 2024-05-10 | 浙江大学 | 一种抗人MICA/Bα3区的单克隆抗体及其应用 |
| CN114369161B (zh) * | 2021-12-28 | 2023-06-23 | 合肥天港免疫药物有限公司 | Mica抗体及其应用 |
| CN114369162B (zh) * | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| CN118027195B (zh) * | 2023-05-06 | 2025-07-04 | 合肥天港免疫药物有限公司 | 亲和力成熟的mica抗体及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| WO1996030511A1 (en) * | 1995-03-29 | 1996-10-03 | The Immunogenetics Research Foundation Incorporated | Polymorphic and multicopy members of mhc gene families |
| CA2275141A1 (en) | 1996-10-29 | 1998-05-07 | Thomas Spies | Cell stress regulated human mhc class i gene |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| WO2003089616A2 (en) | 2002-04-22 | 2003-10-30 | Fred Hutchinson Cancer Research Center | Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions |
| JP4459810B2 (ja) | 2002-08-14 | 2010-04-28 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| CA2565874C (en) | 2004-05-10 | 2017-10-03 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| KR20080032065A (ko) | 2005-06-03 | 2008-04-14 | 제넨테크, 인크. | 푸코실화 수준이 조절된 항체의 생성 방법 |
| PL1919503T3 (pl) | 2005-08-10 | 2015-04-30 | Macrogenics Inc | Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania |
| WO2007055926A1 (en) | 2005-11-03 | 2007-05-18 | Fred Hutchinson Cancer Research Center | Negative immunomodulation of immune responses by nkg2d-positive cd4+ cells |
| FR2894982A1 (fr) | 2005-12-16 | 2007-06-22 | Lab Francais Du Fractionnement | Procede de preparation d'anticorps selectifs des recepteurs fc activateurs |
| WO2007084922A2 (en) | 2006-01-17 | 2007-07-26 | Biolex Therapeutics, Inc. | Compositions and methods for humanization and optimization of n-glycans in plants |
| JP2009529331A (ja) | 2006-03-10 | 2009-08-20 | マクロジェニクス，インコーポレーテッド | 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法 |
| CA2660592C (en) | 2006-05-26 | 2016-07-12 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| CA2656224C (en) | 2006-06-26 | 2018-01-09 | Macrogenics, Inc. | Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof |
| EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
| WO2008036981A1 (en) * | 2006-09-22 | 2008-03-27 | Dana-Farber Cancer Research, Inc. | Methods for treating mica-related disorders |
| CA3011859A1 (en) * | 2007-04-23 | 2008-10-30 | Fred Hutchinson Cancer Research Center | Negative immunomodulation of immune responses by erp5 |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| CA2822366A1 (en) | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| EP3210625B1 (en) | 2011-09-30 | 2019-08-28 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica) |
| BR112014019611A2 (pt) | 2012-02-07 | 2017-06-27 | Innate Pharma | agentes de ligação mica |
| WO2017157895A1 (en) | 2016-03-15 | 2017-09-21 | Innate Pharma | Anti-mica antibodies |
-
2013
- 2013-02-07 BR BR112014019611A patent/BR112014019611A2/pt not_active Application Discontinuation
- 2013-02-07 CN CN201380017820.5A patent/CN104244977A/zh active Pending
- 2013-02-07 US US14/377,274 patent/US10577416B2/en not_active Expired - Fee Related
- 2013-02-07 RU RU2014131317A patent/RU2656183C2/ru active
- 2013-02-07 JP JP2014556052A patent/JP6405242B2/ja active Active
- 2013-02-07 AU AU2013218017A patent/AU2013218017B2/en not_active Ceased
- 2013-02-07 CA CA2862101A patent/CA2862101A1/en not_active Abandoned
- 2013-02-07 EP EP13704064.8A patent/EP2812027A1/en not_active Ceased
- 2013-02-07 SG SG11201404177PA patent/SG11201404177PA/en unknown
- 2013-02-07 WO PCT/EP2013/052439 patent/WO2013117647A1/en not_active Ceased
-
2014
- 2014-07-24 IL IL233793A patent/IL233793B/en active IP Right Grant
-
2020
- 2020-02-28 US US16/804,705 patent/US20200299380A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508757A5 (enExample) | ||
| JP7303314B2 (ja) | Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞 | |
| JP6901493B2 (ja) | 抗ｂｃｍａポリペプチド及びタンパク質 | |
| TWI664289B (zh) | 針對細胞內抗原之單域抗體 | |
| JP2020023523A5 (enExample) | ||
| Kleber et al. | BCMA in multiple myeloma—a promising key to therapy | |
| IL268620B2 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| JP2017505622A5 (enExample) | ||
| JP2019531084A5 (enExample) | ||
| JP2008516970A5 (enExample) | ||
| JP2014039548A5 (enExample) | ||
| JP2017522903A5 (enExample) | ||
| RU2014131317A (ru) | Связывающие mica агенты | |
| CN112119099A (zh) | 三特异性抗原结合蛋白 | |
| AU2014290288A1 (en) | Anti-human papillomavirus 16 E6 T cell receptors | |
| TW201643193A (zh) | 一種抗ｐｄ－１的單克隆抗體及其獲得方法 | |
| JP2016539096A5 (enExample) | ||
| JP2017527275A5 (enExample) | ||
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2013506425A5 (enExample) | ||
| HRP20241316T1 (hr) | Nova anti-sirpa antitijela i njihove terapijske primjene | |
| JP2017512838A5 (enExample) | ||
| TW202233680A (zh) | 具有增加的選擇性之多靶向性雙特異性抗原結合分子 | |
| JP2020503841A5 (enExample) | ||
| WO2019144677A1 (zh) | 抗ox40抗体及其用途 |